scholarly journals Combined Supplementation with Glycine and Tryptophan Reduces Purine-Induced Serum Uric Acid Elevation by Accelerating Urinary Uric Acid Excretion: A Randomized, Single-Blind, Placebo-Controlled, Crossover Study

Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2562
Author(s):  
Oshima ◽  
Shiiya ◽  
Nakamura
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Water Solubility ◽  
Elevated Serum ◽  
Acid Excretion ◽  
Japanese Adult ◽  
Urinary Ph ◽  
Uric Acid Excretion ◽  
Combined Supplementation ◽  
Single Blind

The authors previously confirmed the serum uric acid-lowering effects of the combination of glycine and tryptophan in subjects with mild hyperuricemia. This study examined whether combined supplementation with glycine and tryptophan suppressed the elevation in serum uric acid levels caused by purine ingestion and accelerated urinary uric acid excretion in subjects with lower urate excretion using a randomized, single-blind, placebo-controlled, crossover clinical trial design. Healthy Japanese adult males with lower urate excretion ingested water containing purines in addition to dextrin (placebo), tryptophan, glycine, or a glycine and tryptophan mixture. The combined supplementation with glycine and tryptophan significantly reduced the elevated serum uric acid levels after purine ingestion. Glycine alone and in combination with tryptophan significantly increased urinary uric acid excretion and urate clearance compared with the effects of the placebo. Urinary pH increased by the ingestion of the mixture. These results suggested that the improved water solubility of uric acid due to increased urinary pH contributed to the increase of urinary uric acid excretion.

scholarly journals POS1144 SERUM URIC ACID TO CREATININE RATIO IS ASSOCIATED WITH URINARY URIC ACID EXCRETION IN PATIENTS WITH GOUT

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 851.2-851
Author(s):  
Z. Zhong ◽  
Y. Huang ◽  
X. Huang ◽  
Q. Huang ◽  
Y. Liu ◽  
...  
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Acid Output ◽  
Area Under The Curve ◽  
Roc Curves ◽  
Binary Logistic Regression Analysis ◽  
Creatinine Ratio ◽  
Acid Excretion ◽  
Complete Collection ◽  
Uric Acid Excretion

Background:Underexcretion of uric acid is the dominant mechanism leading to hyperuricemia [1] and the 24-hour urinary uric acid excretion is an important measurement. However, it is inconvenient due to accurate timing and complete collection of the specimen.Objectives:The aim of this study was to investigate the relationship between serum uric acid to creatinine ratio (sUACR) and 24-hour urinary uric acid excretion in gout patients.Methods:A total of 110 gout patients fulfilling 2015 ACR/EULAR classification criteria from Guangdong Second Provincial General Hospital from January 2019 to January 2021 were retrospectively enrolled in this study. Patients were divided into underexcretion group (<3600 μmol/24h) and non-underexcretion group (≥3600 μmol/24h). The correlation between sUACR and 24-hour urinary uric acid excretion was analyzed by the Pearson’s correlations analysis. Receiver operation characteristic (ROC) curves were performed to assess the utility of sUACR for discriminating between underexcretion group and non-underexcretion group. Furthermore, the risk factors of uric acid underexcretion were evaluated using binary logistic regression analysis.Results:sUACR in the underexcretion group was significantly lower than the non-underexcretion group (p=0.0001). Besides, sUACR was positively correlated with 24-hour urinary uric acid excretion (r=0.4833, p<0.0001). Furthermore, ROC suggested that the area under the curve (AUC) of sUACR was 0.728, which was higher that of serum uric acid and creatinine. The optimal cutoff point of sUACR was 5.2312, with a sensitivity and specificity of 71.9% and 67.9%. Logistic analysis results revealed that decreased sUACR (<5.2312) was an independent risk factor of underexcretion of uric acid (OR =5.510, 95% CI: 1.952-15.550, P=0.001).Conclusion:sUACR is lower in gout patients with underexcretion of uric acid and may serve as a useful and convenient marker of assessing underexcretion of uric acid in gout patients.References:[1]Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47: 610–13.Figure 1.A. Comparison of serum uric acid to creatinine ratio between underexcretion group and non-underexcretion group. B. Correlation between serum uric acid to creatinine ratio and 24h uric acid excretion.Disclosure of Interests:None declared.

scholarly journals Chicken uric acid elimination via the uric acid transporters BCRP and MRP4 in the liver, kidneys, and intestines

2018 ◽  
Author(s):  
Xuedong Ding ◽  
Manman Li ◽  
Shoufa Qian ◽  
Yuying Ma ◽  
Tianyi Fang ◽  
...  
Keyword(s):  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Normal Serum ◽  
Control Group ◽  
Cancer Resistance ◽  
Acid Excretion ◽  
Uric Acid Excretion ◽  
Resistance Protein ◽  
Treated Drinking Water

AbstractBreast cancer resistance protein (BCRP) and multidrug resistance protein 4 (MRP4) are involved in uric acid excretion in humans and mice. Despite evidence suggesting that chicken renal proximal tubular epithelial cells participate in uric acid secretion, the roles of BCRP and MRP4 in chickens remain unclear. This study evaluated the relationship between chicken BCRP and MRP4 expression and renal function in the liver, kidneys, and intestines. Sixty 20-day-old Isa brown laying hens were randomly divided into four groups: a control group (NC) and groups provided with sulfonamide-treated drinking water (SD), a diet supplemented with fishmeal (FM), and an intraperitoneal injection of uric acid (IU). Serum uric acid, creatinine, and blood urea nitrogen (BUN) levels were significantly higher in the SD and IU groups than in the NC group. BCRP and MRP4 levels in the SD and IU groups were significantly increased in the kidneys and ileum and decreased in the liver. In the FM group, BCRP and MRP4 were significantly increased in the kidneys and slightly increased in the ileum. These results demonstrate that chicken BCRP and MRP4 are involved in renal and intestinal uric acid excretion. When renal function is impaired, serum uric acid increased and BCRP and MRP4 in the liver, kidneys, and ileum exhibit compensatory increases; when renal function is normal, serum uric acid changes have no effect on ileum BCRP and MRP4 expression. Therefore, this study may provide the references to the uric acid regulation in human.

The Effects of Ginsenosides and Anserine on the Up-Regulation of Renal Aquaporins 1–4 in Hyperuricemic Mice

2019 ◽  
Vol 47 (05) ◽  
pp. 1133-1147
Author(s):  
Yalin Zhang ◽  
Han Su ◽  
Juan Zhang ◽  
Juan Kong
Keyword(s):  
Metabolic Disease ◽  
Renal Function ◽  
Uric Acid ◽  
Serum Uric Acid ◽  
Clearance Rate ◽  
Renal Excretion ◽  
Synergistic Effects ◽  
Acid Excretion ◽  
Urea Nitrogen ◽  
Uric Acid Excretion

Hyperuricemia is a metabolic disease of the kidney that results in decreased uric acid excretion. Here, we aimed to investigate the effects of ginsenosides and anserine on hyperuricemia and the expression of aquaporin (AQP) 1–4, which are indicators of renal excretion. Ginsenosides and anserine were administered separately or together after the establishment of hyperuricemia with adenine in BALB/c mice. Renal function indexes such as serum uric acid, creatinine, and urea nitrogen were measured in each group of mice, and the expression of AQP1–4 in renal tissues was detected. Serum uric acid and urea nitrogen were decreased in the ginsenoside and the anserine +UA groups. Meanwhile, the uric acid excretion and clearance rate were clearly increased in the co-treatment +UA group ([Formula: see text].05). Moreover, ginsenosides or anserine ginsenosides or anserine alone and treatment with both increased the expression of AQP1–4; however, the synergistic effects were more significantly enhanced ([Formula: see text].01). We provide the first reported evidence that ginsenosides and anserine have synergistic effects on uric acid excretion. The improvement in renal function in hyperuricemic mice after treatment with ginsenosides and anserine may result from up-regulation of AQP1–4 expressions.

Effect of Antituberculous Drugs on Serum Uric Acid and Urine Uric Acid Excretion

2015 ◽  
Vol 21 (7) ◽  
pp. 346-348 ◽  
Author(s):  
Worawit Louthrenoo ◽  
Sith Hongsongkiat ◽  
Nuntana Kasitanon ◽  
Suparaporn Wangkaew ◽  
Kanon Jatuworapruk
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Acid Excretion ◽  
Uric Acid Excretion ◽  
Antituberculous Drugs

scholarly journals The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor

2019 ◽  
Vol 24 (S1) ◽  
pp. 92-102
Author(s):  
Daisuke Okui ◽  
Tomomitsu Sasaki ◽  
Masahiko Fushimi ◽  
Tetsuo Ohashi
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Uric Acid Level ◽  
Acid Level ◽  
Serum Uric Acid Level ◽  
Combination Group ◽  
Acid Excretion ◽  
Uric Acid Excretion ◽  
Percent Change ◽  
Urate Reabsorption

Abstract Background Dotinurad, a novel selective urate reabsorption inhibitor (SURI), increases urinary uric acid excretion. The aim of this study is to examine the pharmacokinetics, pharmacodynamics, and safety of dotinurad according to the type of hyperuricemia, with or without concomitant use of xanthine oxidase inhibitor, in uric acid “overproduction type” patients. Methods This open-label clinical pharmacology study was conducted in a hospital. Dotinurad 1 mg was administered for 7 days to hyperuricemic patients with uric acid “overproduction type” (overproduction group, n = 6; and combination group, n = 6) and uric acid “underexcretion type” (underexcretion group, n = 6). In the combination group, topiroxostat 80 mg was used concomitantly. Results No significant differences were observed in pharmacokinetics and safety between overproduction group and underexcretion group, and the percent change in serum uric acid level and the amount of urinary uric acid excretion after administration were comparable. In “overproduction type” patients of combination group, the percent change in serum uric acid level significantly increased and the amount of urinary uric acid excretion significantly decreased compared to those of overproduction group. No clinically meaningful differences were observed in safety between the overproduction group and the combination group. Conclusion In inpatients, differences in hyperuricemic type did not significantly influence the pharmacokinetics, pharmacodynamics, and safety of dotinurad. Moreover, in “overproduction type”, the coadministration of dotinurad and topiroxostat had an add-on serum uric acid lowering effect and suppressed urinary uric acid excretion. Trial registration ClinicalTrials.gov Identifier: NCT02837198.

scholarly journals Vine Tea (Ampelopsis grossedentata) Extract Suppresses Postprandial Uric Acid Levels via Both Inhibition of Xanthine Oxidase and Facilitation of Uric Acid Excretion

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 474-474
Author(s):  
Yoshiki Shimizu ◽  
Tsuyoshi Sakurada ◽  
Sayuri Matsuoka ◽  
Kei Yui ◽  
Takayuki Hosoi
Keyword(s):  
Uric Acid ◽  
Xanthine Oxidase ◽  
Serum Uric Acid ◽  
Area Under The Curve ◽  
Fractional Excretion ◽  
Blood Collection ◽  
Acid Excretion ◽  
Loading Test ◽  
Uric Acid Excretion

Abstract Objectives This study was aimed to evaluate the effect of vine tea extract (VE) which contained ampelopsin (AMP) on postprandial serum uric acid levels. Methods A randomized, placebo controlled, and crossover study was performed from January 2018 to June 2018. The participants were Japanese male whose fasting serum uric acid levels were between 5.0 mg/dL and 7.0 mg/dL. The purine (RNA) loading test was conducted in this study. In brief, after fasting blood collection, the subjects ingested 4 g of yeast RNA and trial supplements (500 mg of VE (150 mg of AMP) or placebo), their blood and urine were subsequently collected every 1 hr for 4 hr. Uric acid and creatinine (Cr) levels in the blood and urine were measured. The primary outcome was postprandial uric acid area under the curve (AUC) and the secondary outcomes were postprandial uric acid, Cr clearance, urinary uric acid excretion, uric acid clearance, and fractional excretion of uric acid (FEUA). To investigate the urate lowering mechanism of VE, effect of VE or AMP on xanthine oxidase (XO) and urate transporter function was assessed in vitro. Results Of 119 participants screened, 36 males who met inclusion criteria were enrolled and the subjects were randomly assigned to two groups. Of these, 16 in X group and 18 in Y group were completed of the study. The values were expressed as mean ± SE. The postprandial uric acid AUC of VE (199.14 ± 62.38 mg · min/dL) was lower than that of placebo (214.41 ± 66.91 mg · min/dL), but it was not significant (P = 0.166). On the other hand, intake of VE induced the increase of urinary uric acid excretion (180 min; VE 0.58 ± 0.03 mg/kg/hr; P0.52 ± 0.03 mg/kg/hr; P = 0.044) and FEUA (180 min; VE 0.58 ± 0.03 mg/kg/hr; P 0.52 ± 0.03 mg/kg/hr; P = 0.044). These results suggest VE facilitate the uric acid excretion. An exploratory efficacy analysis was performed on 23 subjects whose eGFR values were less than 89 mL/min. As a result, the intake of VE suppressed postprandial uric acid elevation in those subjects significantly. AMP and VE inhibited the activity of XO in vitro. In addition, AMP weakly inhibited the function of OAT4, one of the urate reabsorption transporters. Conclusions These results suggested that intake of VE inhibited uric acid synthesis and facilitated of urate excretion, thereby suppression of the elevation of postprandial serum uric acid was observed. Funding Sources This study was supported by FANCL Corporation.

scholarly journals Randomized Controlled Trial of Herbal Extracts (Eugenia polyantha, Apium graveolens, Nigella sativa) and Allopurinol Effect on Serum Uric Acid, Urinary Uric Acid and High Sensitivity C-Reactive Protein Levels in Subject with Hyperuricemia

2019 ◽  
Vol 11 (2) ◽  
Author(s):  
Bantar Sutoko ◽  
Rakhma Yanti Hellmi ◽  
Ika Vemillia W ◽  
Stepanus Agung L
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Nigella Sativa ◽  
Controlled Trial ◽  
Herbal Extract ◽  
Apium Graveolens ◽  
Herbal Extracts ◽  
Acid Excretion ◽  
Uric Acid Excretion ◽  
Randomized Controlled

Background: Eugenia polyantha, Apium graveolens, and Nigella sativa are extracts which in preclinical trial can reduce uric acid serum, increase urinary uric acid excretion. Allopurinol is an inhibitor of the xanthine oxidase enzyme which can also reduce the increase of hsCRP in subjetcs with hyperuricemia.   Objective: To determine the safety and effect of herbal extracts in reducing serum uric acid, increasing uric acid excretion and reducing hsCRP levels in patients with hyperuricemia compared with allopurinol.   Method: This study was a double blind randomized controlled trial (RCT). The subjects were hyperuricemic patients aged ³18 years. The subject was divided into groups that received 3000 mg/day of herbal extracts and allopurinol 100 mg/day for 4 weeks. Evaluation of serum uric acid and urinary uric acid urine were every week, and hsCRP levels was baseline and end of intervention. Other parameters related to the safety of use were examined every 2 weeks.   Results: A number of 44  hyperucemia subjects, 23 subjects received herbal extracts and 21 subjects received allopurinol. The decrease of uric acid serum levels in the herbal extract group was 0,467±1,123;0,600;-2,70-3,00 (p=0.027), while in the allopurinol group 1,11 4±0,813;1,30;-1,30-2,30 (p=0,000). Uric acid excretion in the herbal extract group decrease 71,00±1,970;5,50;-92,00-702,00 (p=0,269) and in the allopurinol group decrease 64,54±1,298;22,00;-29,00-440,0 (p=0.003). The reduction of hsCRP in the herbal extract group was 0.08±0.639; 0.01; -1.55-2.05 (p=0.658), and the allopurinol group was -0.33 ± 0.806; -0.01; -2.73- 0.31 (p=0.256).   Conclusion: Herbal extracts (Eugenia poliantha, Apium graveolens and Nigella sativa) and allopurinol can reduce serum uric acid levels in patients with hyperuricemia. Allopurinol also can reduce urinary uric acid excretion.

Sign in / Sign up

Export Citation Format

Share Document